A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.

Research output: Contribution to journalArticle

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)457-466
JournalCancer Biotherapy & Radiopharmaceuticals
Volume20
Issue number4
Publication statusPublished - 2005
Publication categoryResearch
Peer-reviewedYes